The top 10 medical disruptors of 2018

4. The unprecedented reduction of LDL cholesterol

There is a new class of LDL cholesterol lowering drugs that are expected to be disruptors in the next year. The new drugs are expected to lower cholesterol to unprecedented levels.

When taken with a Statin cholesterol lowering drug, the new class of drugs is expected to lower cholesterol levels by 75%.

The small interfering RNA therapy to lower LDL was also a new innovation in 2017. They are given twice a year instead of monthly or weekly like other treatments.

Dr. Leslie Cho of the Heart & Vascular Institute at the Cleveland Clinic suggests that we will continue to see a new class of agents to lower LDL levels in 2018.

Statin drugs could one day be an over-the-counter drug, said Cho.

Next >>

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW